• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMonsanto

Monsanto Has to Pay $289 Million in Damages in First Roundup Cancer Trial

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
August 11, 2018, 9:51 AM ET
US-ENVIRONMENT-HEALTH-TRIAL
Dewayne Johnson reacts after the verdict was read in the case against Monsanto at the Superior Court Of California in San Francisco, California on August 10, 2018. - A California jury on Friday, August 10, 2018 ordered agrochemical giant Monsanto to pay nearly $290 million for failing to warn a dying groundskeeper that its weed killer Roundup might cause cancer. Jurors found Monsanto acted with "malice" and that its weed killers Roundup and the professional grade version RangerPro contributed "substantially" to Dewayne Johnson's terminal illness. (Photo by JOSH EDELSON / POOL / AFP) (Photo credit should read JOSH EDELSON/AFP/Getty Images)Josh Edelson—AFP/Getty Images

Monsanto Co. was socked with $289 million in damages in the first trial over claims that its Roundup weed killer causes cancer.

Dewayne Johnson, a former school groundskeeper whose doctors didn’t think he’d live long enough learn the verdict, prevailed Friday in San Francisco state court after jurors deliberated for three days. The trial was an important test of the evidence against Monsanto and will serve as a template for litigating thousands of other claims over the herbicide.

Johnson was seeking $412 million in damages. Jurors awarded him $39 million for his losses and $250 million to punish the company after finding it liable for a design defect and failing to warn of Roundup’s risks. Monsanto said it will appeal.

“Today’s decision does not change the fact that more than 800 scientific studies and reviews — and conclusions by the U.S. Environmental Protection Agency, the U.S. National Institutes of Health and regulatory authorities around the world — support the fact that glyphosate does not cause cancer, and did not cause Mr. Johnson’s cancer,” Monsanto Vice President Scott Partridge said in a statement.

Germany’s Bayer AG closed a deal to buy Monsanto for $66 billion in June. If the litigation generates large verdicts against Monsanto, it could have a material impact on Bayer’s bottom line, said Chris Perrella, an analyst for Bloomberg Intelligence. Since Roundup is ubiquitous in modern farming, there’s a “huge potential liability,” though it’s very uncertain it will materialize, he said. Bayer investors might not be aware of the risks because many analysts covering the company focus on pharmaceuticals, Perrella said.

Glyphosate, the main ingredient in Roundup, was first approved for use in Monsanto’s weed killer in 1974. While becoming the world’s most popular and widely used herbicide, the question of whether it causes cancer has been hotly debated by environmentalists, regulators, researchers and lawyers — even as Monsanto has insisted for decades that it’s perfectly safe.

Working for a school district in Benicia, California, about 40 miles east of San Francisco, Johnson mixed and sprayed hundreds of gallons of Roundup. He was diagnosed with cancer in 2014, and in July 2017, after chemotherapy and other treatments, his oncologist gave him six months to live.

Johnson’s lawyers, relying on his testimony and expert witnesses, argued that his exposure, including accidents that got him soaked from head to toe in Roundup, caused his non-Hodgkin’s lymphoma.

Monsanto scientists knew of the cancer risk posed by Roundup as far back as the 1970s, but failed to inform the public and instead engaged in a “deliberate effort to distort the truth” as the weed killer generated hefty returns, Johnson’s lawyer, Brent Wisner, told the jury in closing arguments Tuesday.

“Despite the Environmental Protection Agency’s failure to require labeling, we are proud that an independent jury followed the evidence and used its voice to send a message to Monsanto that its years of deception regarding Roundup is over and that they should put consumer safety first over profits,” Wisner said in a statement after the verdict.

Monsanto argued that the type of cancer contracted by Johnson takes many years to form. The short period between Johnson’s first exposure in 2012 and his diagnosis in 2014 made any connection between his contact and the disease impossible, according to the company.

Monsanto lawyer George Lombardi insisted that science has found no connection between Roundup and non-Hodgkin lymphoma. In fact, Lombardi told the jury, no one has yet figured out what causes the disease.

“We don’t know why people get mycosis fungoides,” he said, using the name of the specific form of cancer Johnson has. “It would be nice if we could tell people why they get it, but we can’t.”

The case is Dewayne Johnson v. Monsanto Co., CGC-16-550128, California Superior Court, County of San Francisco (San Francisco).

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Successthe future of work
As boomer and Gen X bosses retire, working from home will make a major comeback, new research predicts—and it’s all thanks to work-life balance loving Gen Z bosses
By Orianna Rosa RoyleFebruary 17, 2026
17 hours ago
HealthHealth
Confronting Asia’s growing rate of chronic conditions means tackling cultural issues as much as medical ones
By Stuart A. SpencerFebruary 15, 2026
2 days ago
Susan Blumenthal
AICancer
Meet the American spies who helped mammograms save more lives
By Erik GermanFebruary 15, 2026
3 days ago
HealthDietary Supplements
5 Best Nootropics of 2026: Expert Reviewed Supplements
By Christina SnyderFebruary 13, 2026
4 days ago
Big TechGen Z
Analog-obsessed Gen Zers are buying $40 app blockers to limit their social media use and take a break from the ‘slot machine in your pocket’
By Marco Quiroz-GutierrezFebruary 13, 2026
4 days ago
Leesa Sapira Chill
Healthmattresses
Presidents Day Mattress Sales 2026: Find Deals on the Best Sleep Brands
By Christina SnyderFebruary 13, 2026
5 days ago

Most Popular

placeholder alt text
AI
Thousands of CEOs just admitted AI had no impact on employment or productivity—and it has economists resurrecting a paradox from 40 years ago
By Sasha RogelbergFebruary 17, 2026
12 hours ago
placeholder alt text
Economy
$56 trillion national debt leading to a spiraling crisis: Budget watchdog warns the U.S. is walking a crumbling path
By Nick LichtenbergFebruary 17, 2026
13 hours ago
placeholder alt text
Real Estate
A billionaire and an A-list actor found refuge in a 37-home Florida neighborhood with armed guards—proof that privacy is now the ultimate luxury
By Marco Quiroz-GutierrezFebruary 15, 2026
3 days ago
placeholder alt text
Personal Finance
Current price of silver as of Tuesday, February 17, 2026
By Joseph HostetlerFebruary 17, 2026
16 hours ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
7 days ago
placeholder alt text
Economy
Trump crackdown drives 80% plunge in immigrant employment, reshaping labor market, Goldman says
By Nick LichtenbergFebruary 17, 2026
8 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.